HTV and blood transfusions: Focus on seroconversion

Busch, Michael P.

doi:10.1159/000462696

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The yield of p24 antigen screening was estimated from these data by multiplying the duration of the p24 Ag+/Ab-window period by the HIV incidence rate among donors. This resulted in projections of 0.4 to 0.8 Ag+/Ab-units per million donations screened, which translated into a projected detection of 5 to 10 Ag+/Ab-donations per year out of 12 million U.S. donations [18][19][20][21]. These numbers are remarkably consistent with the projections extrapolated from high prevalence settings discussed above.…”

Section: Projections Of Yield Prior To Implementationmentioning

confidence: 52%

“…Extrapolations from these studies to antigen screening of U.S. donors yielded projections for the detection of 7 to 16 Ag+/Ab-units per year. Fourth, several groups developed models for projecting the yield of p24 antigen screening of donors by estimating the frequency at which a seroconverting donor will give blood in the Ag+/Ab-window period [17][18][19][20][21]. This approach relied on combining two estimates.…”

Section: Projections Of Yield Prior To Implementationmentioning

confidence: 99%

See 1 more Smart Citation

The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus Reality

Busch¹,

Stramer²

1998

Transfus Med Hemother

View full text Add to dashboard Cite

Section: Projections Of Yield Prior To Implementationmentioning

confidence: 52%

Section: Projections Of Yield Prior To Implementationmentioning

confidence: 99%

The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus Reality

Busch¹,

Stramer²

1998

Transfus Med Hemother

View full text Add to dashboard Cite

Epidemiology and Prevention of Transfusion‐Associated Human Immunodeficiency Virus Transmission in Sub‐Saharan Africa

McFarland

Mvere²,

Shandera³

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Automated Multiplex Assay System for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNA

et al. 2001

View full text Add to dashboard Cite

We have developed an automated multiplex system for simultaneously screening hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus type 1 (HIV-1) in blood donations. The assay, designated AMPLINAT MPX HBV/HCV/HIV-1 Test (AMPLINAT MPX), consists of virus extraction and target sequence-specific probe capture on specimen preparation workstation GT-X (Roche Diagnostics K.K., Tokyo, Japan) and amplification and detection by TaqMan PCR on the ABI PRISM 7700 Analyzer (PerkinElmer Applied Biosystems, Foster City, Calif.). An internal control (IC) is incorporated in the assay to monitor the extraction, target amplification, and detection processes. The assay yields qualitative results without discrimination of the three targets. Detection limits (95% confidence interval) are 22 to 60 copies/ml for HBV, 61 to 112 IU/ml for HCV, and 33 to 66 copies/ml for HIV-1, using a specimen input volume of 0.2 ml. The AMPLINAT MPX assay detects a broad range of genotypes or subtypes for all three viruses and has a specificity of 99.6% for all three viruses with seronegative specimens. In an evaluation of seroconversion panels, the AMPLINAT MPX assay detects HBV infection an average of 24 days before the detection of HBsAg by enzyme immunoassay. HCV RNA was detected an average of 31 days before HCV antibody. HIV-1 RNA was detected an average of 14 days before HIV-1 antibody and an average of 9 days before p24 antigen. The Japanese Red Cross has been evaluating the AMPLINAT MPX system since October 1999. The clinical performance indicates that the AMPLINAT MPX system is robust, sensitive, and reproducible, with a high percentage of valid assay runs (96.8%), a low false-positive rate (0.34%), and a low IC failure rate (0.24%).

show abstract

HTV and blood transfusions: Focus on seroconversion

Cited by 4 publications

References 15 publications

The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus Reality

The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus Reality

Epidemiology and Prevention of Transfusion‐Associated Human Immunodeficiency Virus Transmission in Sub‐Saharan Africa

Automated Multiplex Assay System for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNA

Contact Info

Product

Resources

About